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Alexandra Filipovich,1 Kenneth McClain,2 Alexei Grom1The Histiocytoses are defined as non-malignant disorders due to abnormal accumulation and behavior of
cells of the mononuclear phagocytic system. The best known histiocytoses, Langerhans cell histiocytosis
(LCH), and hemophagocytic lymphohistiocytosis (HLH), each with an estimated incidence of 1/50,000 to
1/150,000, are sufficiently ‘‘common,’’ complex and costly, to constitute an important problem in medical
practice. At the same time, LCH, HLH and an array of other and more rare histiocytoses are sufficiently
uncommon that most physicians lack the experience to diagnose, let alone care for patients with these
conditions. The pathophysiology of most of the histiocytoses is unknown and, in the case of the widely-
disseminated and potentially fatal forms, treatments to date have been variably effective and sometimes highly
toxic. MAS has been reported to occur in association with almost any rheumatic disease, it is by far most
common in the systemic form of Juvenile Idiopthic Arthritis (SoJIA). It is now recognized that MAS bears
a close resemblance to Hemophagocytic Lymphohistiocytosis or HLH, and MAS is recognized as the major
fatal complication of soJIA.
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The mononuclear phagocytic system consists of
dendritic cells and monocyte/macrophages, histori-
cally referred to as histiocytes. The histiocytoses com-
prise a wide variety of individually rare and diverse
conditions that affect both children and adults, and
range from benign skin lesions to rapidly life-threaten-
ing systemic disorders. Progress in understanding the
molecular and biologic underpinnings of the histiocy-
toses has been hindered by (1) the rarity of individual
disorders, (2) lack of funding for ‘‘orphan’’ diseases,
(3) lack of suitable animal models for many of the his-
tiocytoses, and (4) dispersion of patients with histiocy-
toses among many medical subspecialties.
Mononuclear phagocytes (histiocytes) arise from
the myeloid hematopoietic lineage. Their ultimate
fate, however, in terms of biologic characteristics and
location in the human body, is directed by the cytokineCincinnati Children’s Hospital Medical Center, Cincinnati,
and 2Texas Children’s Cancer Center, Houston, Texas.
isclosure: See Acknowledgments on page S88.
dence and reprint requests: Alexandra Filipovich, MD,
on of BMT & Immune Deficiency, 3333 Burnet Avenue,
7015, Cincinnati, OH 45229 (e-mail: list.filipovich@
c.org).
erican Society for Blood and Marrow Transplantation
/10/161S-0015$36.00/0
6/j.bbmt.2009.11.014and chemokine environments that are elaborated by
other cell lineages. Normal functions of histiocytes,
which are a major component of the innate immune
system, include phagocytosis (housekeeping and recy-
cling), and antigen presentation and activation of the
adaptive immune system through direct contact and
cytokine signaling. Histiocytes normally participate
in wound and tissue repair and have key roles in initi-
ation, as well as, regulation of inflammation.
The true incidences of histiocytoses are not
known, and may vary according to ethnicity and
inbreeding (as in the case of the autosomal recessive
disease HLH, which is more common in some isolated
regions of the world and in populations where consan-
guinous marriages are practiced).
The histiocytic disorders are generally defined by
their constitutive cell type, on the basis of widely recog-
nized pathologic and histologic criteria (Table 1). Pa-
thologists now accept that that these morphologic and
biochemical criteria must also be paired with a relevant
clinical context, for example, clinicopathologic criteria.LCH
LCH, published as such in 1868 by the 21-year-old
Paul Langerhans, is reported to be the most common of
the histiocytoses. Reports of a nonfatal disease with pain-
ful skull lesions date back to Hippocrates. Between 1893
and 1920 Hand, Sch}uller and Christian elaborated the
Table 1. Classification of Histiocytic Disorders
Benign disorders of varying biologic behavior
a. Dendritic cell related
Langerhans cell histiocytosis
Juvenile xanthogranuloma and related disorders including:
- Erdheim-Chester disease
- Solitary histiocytomas with juvenile xanthogranuloma phenotype
- Secondary dendritic cell disorders
b. Monocyte/macrophage related
Hemophagocytic lymphohistiocytosis
Familial and sporadic
Secondary hemophagocytic syndromes:
- Infection associated
- Malignancy associated
- Autoimmune associated (MAS)
- Other
Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)
Solitary histiocytoma of macrophage phenotype
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insipidus. Thus, in the medical literature LCH has
been referred to as Hand-Schuller-Christian disease
and Histiocytosis ‘‘X’’ (denoting the uncertainty about
the disease and its pathogenesis).
It is now well recognized that LCH can present at
any age from the neonatal period to old age. The spec-
trum of clinical presentations is broad and protean.
LCH lesions may spontaneously regress, or repeatedly
‘‘reactivate’’ contributing to long-term disabilities
such as diabetes insipidus and neurodegenerative
disease. Life-threatening forms of LCH, previously
referred to as Letterer-Siwe disease, typically present
in infancy and clearly require intensive therapy and,
sometimes, salvage therapy such a allogeneic bone
marrow transplantation to cure the children.
Clinical involvement with LCH can be highly vari-
able, but most often involves bony lesions (present in
about 80% of cases), which may be painful or painless,
as is common with skull lesions. Skin involvement, typ-
ically papulosquamous lesions, often affecting the
scalp (and frequently mistaken for cradle cap, sebor-
rhea) is reported in 30% to 60% of patient series.
Soft tissue swelling, often in proximity to bony lesions,
external ear drainage, enlargement of lymph nodes and
thymus, and gum hypertrophy with premature erup-
tion of baby teeth, represent the constellation of symp-
toms that are relatively easily treated. More serious
systemic involvement (eg, as described for Letterer-
Siwe disease) includes fevers, hepatosplenemagaly,
liver dysfunction, and hematopoietic failure 6 intesti-
nal involvement. The latter findings are typical of the
widely disseminated form of LCH seen in young in-
fants, which carries a high mortality rate.Etiopathogenesis of LCH
The name LCH suggests that the dendritic Lang-
erhans cell usually located in the dermal/epidermal
border of the skin is the key cell of the disease. To
date, this has not been proven. Over the years LCHhas been classified as a neoplasm, a reactive disorder
or an aberrant immune response. Associated genetic
defects, if any, have not been described. LCH cells
are considered pathologic in that they bear heteroge-
neous characteristics not normally identified in the
Langerhans cells, which are typically resident to the
skin.The granulomatous lesions of LCH, which can
be found in nearly any organ, represent an accumulation
of normal inflammatory cells including eosinophils,
lymphocytes (especially T cells) and macrophages in ad-
dition to the LCH cells. Although clonal accumulations
of LCH cells have been described, current thinking
suggests that LCs home to the skin during embryonic
development and, like segments of skin within which
they reside, naturally expand from single progenitor
cells rather than through neoplastic proliferation.
Although there is ample evidence that LCH cells
react to the local cytokine and chemokine environ-
ment, and may be particularly susceptible to signals
from local T cells, the pathogenesis of LCH remains
elusive. In the past, studies of LCH biology have
focused largely on histochemistry to characterize ab-
normalities in LCH cells versus normal Langerhans
cells. Such approaches have been limited by the specific
tools used and the specific hypotheses that were being
tested.
More recently, the genome wide discovery
approach has been used to identify the key active mol-
ecules and pathways in human LCH samples (C. Allen
and K. McClain, Texas Children’s Hospital, largely
unpublished). Purified CD2071 (langerin1) cells and
CD31 cells isolated from LCH lesions have been com-
pared to their counterparts from normal tissues. Micro-
array experiments yielded some expected results, but
also some surprising results. The 29 genes upregulated
more than 4-fold in the pathologic LCH LCs included
some genes previously described as differentially ex-
pressed, including E-cadherin and RANTES. Addi-
tionally, some genes not previously associated with
LCH that regulate lymphocyte activation and migra-
tion, including osteopontin, vanin-1, and LAMP-3,
were upregulated in LCH LCs. However, failure to
identify differences in expression in specific genes pre-
viously published to be associated with these functions
was unexpected, including CCR6 and CCR7, cell
surface markers involved in T cell activation (CD40,
CD80, CD86), pro-inflammatory cytokines (tumor ne-
crosis factor [TNF]-a, interferon [IFN]-g, interleukin
[IL]-1a, IL-1b, leukemia inhibitory factor [LIF], IL-4,
IL-10, tumor growth factor [TGF]-b), genes involved
in regulation of apoptosis (Flt-3, Flt3-ligand, bcl-2), or
markers of cell proliferation (Ki67, PCNA, p53). The
comparative gene expression profile observed does not
appear consistent with one of the prevailing models of
LCH cells as (possibly malignant), activated, immature
dendritic cells that independently elaborate a ‘‘cytokine
storm.’’ So, back to ‘‘Histiocytosis X.’’
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The diagnosis of LCH is based on the histologic
and immunophenotypic examination of lesional tissue.
The primary diagnostic feature is the morphologic
identification of characteristic LCH cells. Additionally,
positive staining of the lesional cells with CD1a and/or
Langerin (CD207) is required for definitive diagnsosis.
Guidelines for treatment of LCH have been elabo-
rated by the LCH working party of the Histiocytosis
Society, and are available on the Web pages of that or-
ganization. The recommendations are briefly summa-
rized here. The goal of therapy in LCH is to decrease
the activity and proliferation of histiocytes , lympho-
cytes, and other immune cells that contribute to disease
activity.
Patients with disease that is localized to skin, bone,
and lymph nodes (defined as ‘‘nonrisk’’ organs) gener-
ally have a good prognosis and require minimal treat-
ment. However, patients with lesions in ‘‘risk’’ organs
(liver, spleen, lung, bone marrow) have a worse overall
prognosis in terms of morbidity and mortality. Patients
with LCH in the central nervous system (CNS), verte-
brae, facial bones, or bones of the anterior or middle
cranial fossa are at higher risk for morbidity and recur-
rent disease. LCH in the orbit, mastoid, or temporal
skull regions are classified as ‘‘CNS risk’’ because of in-
creased frequency of associated diabetes insipidus (DI)
and other endocrine or parenchymal brain lesions.
LCH in only 1 bone of ‘‘nonrisk’’ location is generally
benign, and the disease responds well to several
treatment modalities including observation, surgical
excision, steroid injection, or indomethacin therapy.
As a result of evaluation of several sequential treat-
ment trials, the Histiocyte Society has stratified
patients with LCH into ‘‘low’’ (LR) and ‘‘high’’ (HR)
risk groups based on outcomes related to extent and
location of the LCH lesions. LR patients include
patients with skin, bone, lymph node, and pituitary in-
volvement. Patients with lung, liver, spleen, and bone
marrow involvement usually have a worse prognosis
and are considered higher risk. However, children
with lung LCH without involvement of other HR
organs respond to treatment much better than those
with other HR organs [1].
Preliminary results from the LCH-III study show
that HR patients treated with velban/prednisone/mer-
captopurine did as well as those randomized to also re-
ceive intravenous methotrexate during induction and
oral methotrexate during continuation treatment.
When patients do not respond adequately by the sixth
week of treatment it is recommended that they now be
switched to a salvage protocol (LCH-S-2005) with
high doses of cladribine and cytarabine [2]. The LR pa-
tients treated with velban and prednisone for 12 months
had fewer relapses than those treated for 6 months.
Further follow-up data is needed to confirm this.Retrospective analysis of ‘‘CNS-risk’’ patients
treated with only surgery, steroid injection, radiation
therapy, or a single chemotherapy drug have a 40%
incidence of DI [3]. If they receive velban and predni-
sone for 6 months the incidence of DI is 20% [4].
Complications of developing DI include a 50%
incidence of anterior pituitary hormone deficiencies
and 50% incidence of developing radiographic or
clinical evidence of a neurodegenerative syndrome
(ND-CNS-LCH) [5]. Twenty-five percent of patients
diagnosed with ND-CNS-LCH with the radiographic
abnormalities of T2 hyperintense signals in the cere-
bellum, basal ganglia, or pons have clinical symptoms
that include ataxia, dysarthria, dysmetria, learning,
and behavior difficulties [5]. Treatment with intrave-
nous immunoglobulin or trans-retinoic acid resulted
in stabilization, but no improvement of the symptoms.
A recently published study describes the efficacy of
cytarabine treatment of patients with ND-CNS-
LCH [6].
LCH cells express CD1a and CD52—potential
targets for treatment with monoclonal antibodies
anti-CD1a, which is under development, and anti-
CD52 (Campath) [7]. Some LCH patients have insuffi-
cient responses to the salvage therapy and are candidates
for stem cell transplant. Patients with severe hemato-
logic dysfunction, in particular, may be directed to
hematopoietic cell transplant (HCT).
HCT for LCH
HCT is a theoretically attractive option for man-
agement of refractory LCH because of its immuno-
modulatory potential. Many published reports have
described 1 or a few cases, and date back more than
20 years. The collected experience with HCT for
LCH in the literature up until 2008 was recently com-
piled [8]: 44 pediatric cases, of which the vast majority
presented in infancy. The majority of patients in that
review received myeloablative conditioning, typically
consisting of combinations of Busulfan, Cytoxan, VP-
16, and/or TBI. Survival data was available for 34/44
cases indicating 59% 5-year overall survival (OS) for
patients with allogeneic donors, compared with 25%
OS with the use of autologous HCT. Infections were
the major cause of death in this historic review, fol-
lowed by regimen related toxicity. Importantly, 24 of
26 patients were disease free at last follow-up. The
most recently published series from Japan described
15 children transplanted at a median age of 23 months
since 1995. Ten of 15 HCT utilized allogeneic cord
blood donors. Ten-year OS in this group was 73%,
but only 55% among the 9 patients who had LCH
‘‘risk organ’’ involvement at the time of HCT [9].
There has been increased interest in the use of
reduced-intensity conditioning (RIC) for these cases
[10]. The largest single-center experience with RIC
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All patients received Fludarabine in their pre-HCT
regimen, 8 received Melphalan; additionally total lym-
pholid irradiation (TLI) or total-body irradiation
(TBI), antithymocyte globulin (ATG), or Campath
were added in a varying number of this patient group.
Seven of 9 are long-term disease-free survivors [11].
Despite these more encouraging results, allogeneic
HCT for HR LCH has been associated with signifi-
cant mortality. HCT is a reasonable option for this pa-
tient population but the optimal timing, preparative
modalities, and donor source(s) remain unclear.HLH
HLH is a collection of nonmalignant, but fre-
quently life-threatening disorders, associated with an
ever-growing list of genetic and acquired causes. The
predominant clinical findings of HLH are fevers (often
hectic and persistent), cytopenias, hepatitis, and
splenomegaly.
Until recently, it was widely believed that symp-
toms of HLH because of genetic causes arose during
infancy and early childhood. With the more wide-
spread availability of genetic testing, it is apparent
that the first significant episode of HLH can occur
throughout life from prenatal presentations through
the seventh decade. Distinctions between primary (ge-
netically determined) and secondary (acquired) forms
of HLH become increasingly blurred together as new
genetic causes are identified and patients who develop
HLH beyond early childhood or in the contexts of
EBV infection or autoimmune disease are being found
to share some of the same genetic etiologies.
Etiopathogenesis of HLH and Related Disorders
Hemophagocytic lymphohistiocytosis (HLH) re-
sults when critical regulatory pathways responsible for
the natural termination of immune/inflammatory re-
sponses are disrupted or overwhelmed. In HLH, path-
ologic genetic defects alter normal crosstalk between
innate and adaptive immune responses in a manner
that compromises homeostatic removal of cells which
are superfluous or dangerous to the organism. The
result is excessive and persistent activation of antigen
presenting cells (histiocytes) and T lymphocytes. The
clinical findings associated with systemic inflammation
such as prolonged high fevers and hepatitis reflect this
immunologic perturbation.
Currently, HLH (FHL:OMIM 267700, 603553)
includes the autosomal recessive genetic disorders as
well as the ‘‘secondary’’ forms. In recent years, many
more cases of hemophagocytic disorders are being di-
agnosed, especially in the context of severe inflamma-
tory reactions to viral exposure including, in addition
to Epstine-Barr virus (EBV)-HIV and Avian influenza.HLH is characterized by multisystem inflamma-
tion—a reactive process resulting from prolonged
and excessive activation of antigen presenting cells
(macrophages, histiocytes) and CD81 T cells, and ex-
cessive proliferation and ectopic migration of T cells.
Abnormalities in the function (and sometimes quan-
tity) of NK cells have been observed in a proportion of
patients with all forms of HLH. Natural killer (NK)
and natural killer T (NKT) cells, in particular, play
a major role in maintaining a healthy threshold of im-
mune responsiveness to noxious external stimuli, and
are critical to prevention and control of autoimmune
conditions and severe reactions to viral infections. NK
cells (using their cytotoxic and cytokine-mediated
mechanisms) form a front line of defense against intra-
cellular pathogens, such as viruses, which infect non-
lymphoid tissues early upon entry into the organism.
NK cells modulate the initial responses of antigen-
presenting cells to incoming pathogens (likely through
cytokine signaling), thus attenuating the signals subse-
quently communicated to antigen-specific T cells. NK
cells likely also play a role in culling activated T cells
and histiocytes in later stages of antigen-driven activa-
tion, contributing to the natural contraction of immune
responses.
Also critical to the contraction process of active T
cell populations is the mechanism of activation-induced
apoptosis, recently shown to be defective in X-Linked
Lymphoproliferative syndrome type1 (XKLP1) [11].
As with NK cell cytotoxicity, this process is driven by
granule-mediated cytotoxicity .
Studies of cytokine levels in blood and tissues have
indicated persistently elevated circulating levels of
multiple proinflammatory cytokines during symptom-
atic disease. It is currently believed that ‘‘hypercytoki-
nemia’’ generated by uncontrolled activation of
histiocytes and T cells underlies the progressive organ
dysfunction that can eventually lead to death. These
symptoms and signs include fevers, hyperlipidemia,
endothelial activation/coagulopathy, hepatitic triaditis,
central nervous system (CNS) vasculitis and demyelin-
ation, inflammatory lung disease with acute respiratory
distress syndrome (ARDS), and marrow hyperplasia or
aplasia. Hemophagocytosis, for which finding the
disorder was named, is a hallmark of activated macro-
phages/histiocytes.Genetic Causes of HLH and Related Disorders
To date, autosomal recessive genetic defects asso-
ciated with HLH are related to one another along the
pathway of granule-mediated cytotoxicity. These ge-
netic defects interrupt mechanisms responsible for
triggered apoptosis (mediated by cytotoxic cells upon
the target cell). Other causal defects interrupt activa-
tion induced apoptosis (putative suicide of activated
T cells). The first gene reported in 1999 to be a cause
Table 2. Diagnostic Criteria
A molecular diagnosis consistent with HLH (see above) or at least 5 of 8
criteria listed below
 Fever, typically persistent daily
 Splenomegaly
 Bicytopenia: Hb <9 g/dL; platelets <100  109/L; neutrophils <109/L
 Hypertriglyceridemia and/or hypofibrinogenemia
 Hemophagocytosis in bone marrow (BM), spleen, lymph node, or CSF
 Low or absent NK function (note: only present in approximately 50% of
HLH patients)
 Elevated ferritin (>500 mg/L)
 Soluble CD25 (IL2Ra) above normal limits for age.
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forming cytolytic protein synthesized in cytotoxic
lymphocytes and sequestered, along with granzyme
serine proteases, in secretory cytotoxic granules.
When cytotoxic cells contact their targets, the intracel-
lular cytoskeletal scaffold (the microtubule organizing
center [MTOC]) is rotated to focus on the contact site
where the cytotoxic immunologic synapse forms. Cyto-
toxic granules are carried along the MTOC toward the
immunologic synapse where they degranulate allowing
perforin and Granzyme B to enter the contact zone,
permeabilize the target cell membrane, and enable deliv-
ery of Granzyme B into the target cell. Once internal-
ized, Granzyme B initiates both caspase-dependent
and caspase-independent apoptotic pathways, killing
the target cell.
A second gene responsible for HLH (FHL3) was
reported in 2003: MUNC 13-4. MUNC 13-4 was
described as essential for cytolytic granule fusion with
other structures related to the cytoplasmic membrane
in the process of degranulation [13]. The gene defect
responsible for FHL4 is Syntaxin 11 [14], which has
been shown, as in MUNC 13-4 deficiency, to result
in defective degranulation. Syntaxin 11 is a member
of the SNARE protein family, which facilitates fusion
in intracellular membrane trafficking events. More
recently, mutations in the syntaxin binding protein,
MUNC 18-2, have been identified to be associated
with HLH (tentatively named FHL5) [15].
Related hemophagocytic disorders occur with sig-
nificant frequency in 5 other genetic diseases, several
of which have been linked with defective cytotoxic
function. Three distinct immunodeficiencies that are
typically associated with pseudoalbinism because of
defects in lysosomal trafficking have been associated
with life-threatening episodes of HLH: Chediak Higa-
shi syndrome (LYST, or CHS1), Griscelli syndrome
(Rab27A), and Hermansky-Pudlak syndrome type II
(AP3B1). Rab27a, a small Rho GTPase, interacts di-
rectly with MUNC 13-4 and is thought to play a role
in docking of the cytotoxic granules on the MTOC.
HLH following exposure to EBV and less com-
monly other viruses, termed fulminant infectous
mononucleosis, is the most frequent life-threatening
complication of XLP1. XLP1 is caused by hemizygous
mutations in SH2D1A encoding SAP (SLAM Associ-
ated Protein), which lead to abnormal NK cell re-
sponses and iNKT cell deficiency. Recent research
suggests that lymphocytes from patients with XLP1
demonstrate decreased activation-induced apoptosis,
which contributes to the lymphoproliferative clinical
phenotypes. XLP2, caused by hemizygous mutations
in XIAP, or BIRC4, has been described in males who
develop sporadic as well as EBV-associated HLH
[16]. Patients with XLP1 and XLP2 may survive into
adulthood in good health before succumbing to a life-
threatening complication of their underlying disease.Thus, lack of prior significant medical history should
not exclude consideration of these diagnoses.
Taken together, the 9 genetic disorders described
above still account for less than half of the diagnosed
cases of HLH in children, including many familial
cases still awaiting molecular defiinition.
Diagnosis of HLH
The first significant episode of FHL can occur
throughout life, including in utero. Despite attempts
to differentiate primary from secondary or reactive
forms of HLH, the symptomatic presentations are
highly overlapping, and a significant proportion of pa-
tients diagnosed with ‘‘secondary’’ HLH are at risk of
dying from the disease. In the most typical form of
FHL, the clinical course is characterized by prolonged
fevers and hepatosplenomegaly. Neurologic symp-
toms may dominate the initial clinical course with sei-
zures and/or ataxia. Neurologic findings may be highly
variable. Standard blood testing typically reveals cyto-
penias—especially anemia and thrombocytopenia,
liver dysfunction, hypofibrinogenemia, hypertrigly-
ceridemia, hypoalbuminemia, and hyponatremia. In
the early days to months of the disease, symptoms
may improve spontaneously, followed by clinical exac-
erbations. Importantly, hemophagocytosis may not be
obvious on bone marrow biopsy examination early in
the course of the disease.
To assist with the rapid diagnosis of HLH, the His-
tiocyte Society has developed a set of diagnostic guide-
lines that encompass both clinical and laboratory
findings [17]. With additional experience these diagnos-
tic criteria have been modestly modified, as shown in
Table 2. A constellation of these features in the absence
of a family history or specific genetic diagnosis can con-
tribute to a provisional diagnosis of HLH and support
the need for initiation of HLH-specific therapy.
Additional criteria for provisional diagnosis of
HLH include elevated levels of ferritin [18] and solu-
ble IL2Ra (sCD25) [19]—both markers of generalized
inflammation. Ferritin is induced during the protective
anti-inflammatory process of macrophage scavenging
of heme through the CD163 receptor, as is IL-10. In
the majority of FHL cases, NK function is low or ab-
sent, although the number of circulating NK cells
(CD561/161) are generally normal. However, the
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cially during active symptomatic disease, should not
preclude a diagnosis of FHL or secondary HLH.
Symptoms of CNS dysfunction, cerebral spinal
fluid (CSF) pleocytosis, or findings of foci of inflamma-
tion by CNS magnetic resonance imaging (MRI) scan-
ning, are found in nearly half of patients with HLH
during the first few months after initial diagnosis.
Treatment of HLH
Because HLH can be rapidly fatal without specific
intervention, it is recommended that treatment be
started when there is a high clinical suspicion, even
when results of some diagnostic studies are still pend-
ing. Retrospective review of FHL 25 years ago de-
scribed mean survival of less than a month after
symptomatic onset and 5% overall survival at 1 year af-
ter diagnosis. Today, effective initial therapy HLH
(FHL) consists of combinations of proapoptotic che-
motherapy and immunosuppressive drugs targeting
the hyperactivated T cells and histiocytes. Commonly
used and effective agents include: Etoposide (VP-16),
steroids, and ATG antibodies.
HCT for HLH
Definitive treatment and potential cure of FHL is
only achieved by HCT. Projected survival rates 5 years
from diagnosis range from 50% to 70% [20]. The best
results following myeloablative conditioning have
been achieved when HLA-matched related or unre-
lated donors were used, and CNS disease was absent
or quiescent at the time of HCT. The largest series
in the literature using unrelated donors reported out-
comes of 91 patients transplanted in the United States
between 1989 and 2005. Most patients were condi-
tioned with Busulfan, cytoxan, and VP-16 with or
without ATG. Early mortality rates after HCT were
unacceptably high: 35% at day 100; projected ‘‘cure’’
for approximately 50% of patients. Early deaths were
attributable to infection, graft-versus-host disease
(GVHD), nonengraftment, venoocclusive disease, and
pneumonitis. In addition a significant number of
deaths were attributed to HLH reactivation. In con-
trast, patients who survived beyond day 100 with
durable engraftment remained free of HLH at last
follow-up [21]. Very similar results were reported for
61 patients who underwent HCT over a 17 year period
in Italy [22] and 43 patients with familial HLH in Ja-
pan [23]. The Japanese series also included 14 cases
of EBV-associated HLH who experienced a somewhat
better long-term survival: 86%.
More recently, use of RIC prior to HCT has been
investigated [24]. To date, most cases of RIC HCT for
HLH have employed Campath, which specifically
targets the T cells and antigen-presenting cells (APCs)
involved in HLH pathogenesis. Experience at severalcenters is consistent with superior early posttransplant
survival. Approximately half of patients with HLH
treated with RIC, however, experience mixed donor
chimerism, which may be unstable in the early months
posttransplant, and raises concerns for subsequent
HLH relapse.
Macrophage Activation Syndrome (MAS)
MAS is a severe, potentially fatal condition associ-
ated with excessive activation and expansion of macro-
phages and T cells leading to an overwhelming
inflammatory reaction. The main manifestations of
MAS include fever, hepatosplenomegaly, lymphade-
nopathy, severe cytopenias, serious liver disease, and
coagulopathy consistent with disseminated intravascu-
lar coagulation [25]. The pathognomonic feature of
MAS is often found in bone marrow: hemophagocyto-
sis. Although MAS has been reported to occur in asso-
ciation with almost any rheumatic disease, it is by far
most common in the systemic form of Juvenile Idi-
opthic Arthritis (SoJIA). Systemic Lupus Erythemato-
sus and Kawasaki disease are 2 other examples of
conditions in which MAS appears to occur somewhat
more frequently than in other rheumatologic diseases
[26,27]. It is now recognized that MAS bears a close
resemblance to HLH. The true incidence of MAS
may be underestimated because relatively mild cases
of MAS often remained unrecognized. Indeed, despite
the lack of diagnostic criteria, because of increasing
awareness of MAS, this syndrome is being diagnosed
more and more frequently. Recent evidence suggests
that mild subclinical MAS might be occurring in as
many as one-third of patients with active systemic
disease, and may be the first manifestation of soJIA.
Infections or change in medications may precede the
diagnosis of MAS; in most patients MAS is triggered
by a flare of the underlying rheumatologic disease.
Published observations suggest that, as in HLH,
MAS patients have profoundly depressed NK cell
function, often associated with abnormal perforin
expression [28-30], and these abnormalities are often
associated with specific perforin [31] and MUNC13-
4 [32,33] polymorphisms.
Diagnosis and Treatment of MAS
There are no validated diagnostic criteria for MAS,
and early diagnosis is often difficult. Thus, in a patient
with persistently active underlying rheumatologic dis-
ease, a fall in the erythrocyte sedimentation rate (ESR)
and platelet count, particularly in a combination with
persistently high C-reactive protein (CRP) and in-
creasing levels of ferritin, should raise a suspicion of
impeding MAS. The diagnosis of MAS is usually
confirmed by the demonstration of hemophagocytosis
in the bone marrow. Assessment of the levels of
sIL2Ra and sCD163 in serum may help with the
timely diagnosis of MAS. Although mild elevation of
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including JIA and SLE [34], a several-fold increase in
the levels of sIL2Ra in these diseases is highly sugges-
tive of MAS [35].
The application of the HLH diagnostic criteria to
systemic JIA patients with suspected MAS is problematic.
Some of the HLH markers such as lymphadenopathy,
splenomegaly, and hyperferritinemia, are common fea-
tures of active systemic JIA itself, and therefore, do not
distinguish MAS from a conventional systemic JIA flare.
Patients with systemic JIA often have increased white
blood cell and platelet counts as well as serum levels of fi-
brinogen as a part of the inflammatory response seen in
this disease. Therefore, when they develop MAS, they
reach the degree of cytopenias and hypofibrinogenemia
seen in HLH only at the late stages of the syndrome
when medical management becomes challenging. This
is even more problematic for the diagnosis of MAS in
patients with sytematic lupus erythematosus (SLE) in
whom autoimmune cytopenias are a common and diffi-
cult to distinguish from those caused by MAS.
Early recognition of this syndrome and immediate
therapeutic intervention to produce a rapid response
are critical. Prompt administration of more aggressive
treatment in these patients may, in fact, prevent devel-
opment of the full-blown syndrome. To achieve rapid
reversal of coagulation abnormalities and cytopenias
most clinicians start with intraveneous methylprednis-
olone pulse therapy (30 mg/kg for 3 consecutive days)
followed by 2 to 3 mg/kg/day divided in 4 doses. After
normalization of hematologic abnormalities and reso-
lution of coagulopathy, steroids are tapered slowly to
avoid relapses of MAS. Not uncommonly, however,
MAS appears to be corticosteroid resistant, with
deaths being reported even among patients treated
with massive doses of steroids.
Parenteral administration of cyclosporine A has
been shown to be highly effective in patients with cor-
ticosteroid-resistant MAS [36]. The utility of biologic
drugs in MAS treatment remains unclear. Although
TNF inhibiting agents, biologics that neutralize
IL-1, and IL-6 have been reported to be effective in
occasional MAS patients [37]; other reports describe
patients in whom MAS occurred while they were
receiving these agents [38].
Based on some success with intravenous immuno-
globulin (IVIG) administration in virus-associated
reactive HLH, this treatment might be effective in
MAS triggered by viral infection. If MAS, however,
is driven by EBV infection, Rituximab, a monoclonal
antibody that depletes B lymphocytes, the main type
of cells harboring EBV virus should be used [39].HCT for MAS
No concerted effort to apply allogeneic HCT for
definitive treatment of MAS has yet been made.However, it is likely that some patients, defined as
HLH and/or with associated genetic defects, have un-
dergone HCT. Given the high mortality associated
with MAS as it is currently managed, the option of
allogeneic HCT using less intensive conditioning pro-
tocols, is reasonable to consider, especially in cases of
severe or recurrent MAS episodes. Indeed, sometimes
fatal, MAS was observed as a complication of pro-
longed T cell immunodeficiency in early trials of
autologous HCT for severe progressive systemic or
polyarticular juvenile idiopathic arthritis. These ex-
periments of nature suggested a failure to control the
underlying condition given the patient’s genetically
predisposed hematopoietic cells [35].ACKNOWLEDGMENTS
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